| Literature DB >> 18622271 |
Steven K Takemoto1, Wolfgang Arns, Suphamai Bunnapradist, Louis P Garrison, Lluis Guirado, Zoltan Kalo, Gabriel Oniscu, Gerhard Opelz, Maria Piera Scolari, Sergio Stefoni, Magdi Yaqoob, Daniel C Brennan.
Abstract
Transplantation offers a unique opportunity to demonstrate the complementary roles of randomized controlled trials and outcome research. The surgery and collaboration necessary for the transplant procedure makes randomization and blinding difficult. Because essentially every recipient is included in a transplant registry, sampling bias is minimized. Regulatory agencies generally do not consider outcomes research when assessing efficacy of new drugs or medical interventions. This workgroup summary examines the suitability of outcomes research to complement results of randomized controlled trials and related issues: efficacy versus effectiveness, internal versus external validity, data types, limitations, and analysis methodologies. Many advances in outcomes research have been pioneered in transplantation. A case is made for regulatory and reimbursement authorities to use outcomes research when making efficacy, effectiveness, and coverage decisions in transplantation.Mesh:
Year: 2008 PMID: 18622271 DOI: 10.1097/TP.0b013e31817d4df5
Source DB: PubMed Journal: Transplantation ISSN: 0041-1337 Impact factor: 4.939